Body mass index and cardiorespiratory fitness in persons with multiple sclerosis

Sebastião, Émerson; Motl, Robert W.

doi:10.1111/ane.12959

Cited by 6 publications

(3 citation statements)

References 26 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity predicts adverse clinical outcomes and treatment responses in rheumatoid arthritis, systemic lupus erythematosus and psoriasis, [88][89][90] worsens functional capacity in systemic sclerosis, 91 increases the prevalence and worsens the severity of asthma, 92 has deleterious effects in inflammatory bowel disease and multiple sclerosis, 93,94 and contributes to the progression of diabetes, non-alcoholic steatohepatitis and chronic kidney disease. [95][96][97] By acting as a broad accelerant of systemic inflammation, obesity potentiates the likelihood of heart failure (particularly HFpEF) in patients who are already prone to its development.…”

Section: Obesity As a Link Between Systemic Inflammation And Metabolimentioning

confidence: 99%

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

Packer

Lam

Lund

et al. 2020

European J of Heart Fail

112

109

View full text Add to dashboard Cite

Accumulating evidence points to the existence of an inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction (HFpEF), which is characterized by biomarkers of inflammation, an expanded epicardial adipose tissue mass, microvascular endothelial dysfunction, normal-to-mildly increased left ventricular volumes and systolic blood pressures, and possibly, altered activity of adipocyte-associated inflammatory mediators. A broad range of adipogenic metabolic and systemic inflammatory disorders-e.g. obesity, diabetes and metabolic syndrome as well as rheumatoid arthritis and psoriasis-can cause this phenotype, independent of the presence of large vessel coronary artery disease. Interestingly, when compared with men, women are both at greater risk of and may suffer greater cardiac consequences from these systemic inflammatory and metabolic disorders. Women show disproportionate increases in left ventricular filling pressures following increases in central blood volume and have greater arterial stiffness than men. Additionally, they are particularly predisposed to epicardial and intramyocardial fat expansion and imbalances in adipocyte-associated proinflammatory mediators. The hormonal interrelationships seen in inflammatory-metabolic phenotype may explain why mineralocorticoid receptor antagonists and neprilysin inhibitors may be more effective in women than in men with HFpEF. Recognition of the inflammatory-metabolic phenotype may improve an understanding of the pathogenesis of HFpEF and enhance the ability to design clinical trials of interventions in this heterogeneous syndrome.

show abstract

Section: Obesity As a Link Between Systemic Inflammation And Metabolimentioning

confidence: 99%

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

Packer

Lam

Lund

et al. 2020

European J of Heart Fail

112

109

View full text Add to dashboard Cite

show abstract

“…In addition, the loss of muscle is directly associated with an increase in body fat in MS patients [ 11 ]. This also causes a rise in inflammation [ 12 ], resulting in a loss in respiratory capacity and fatigue [ 13 ]; therefore, the patient’s disability and the progression of the disease are increased [ 14 ]. In addition, an increase in body fat is associated with a greater expression of the butyrylcholinesterase enzyme (BuChE) in blood serum [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Possible Role of Butyrylcholinesterase in Fat Loss and Decreases in Inflammatory Levels in Patients with Multiple Sclerosis after Treatment with Epigallocatechin Gallate and Coconut Oil: A Pilot Study

et al. 2021

View full text Add to dashboard Cite

(1) Background. Multiple sclerosis (MS) is characterised by the loss of muscle throughout the course of the disease, which in many cases is accompanied by obesity and related to inflammation. Nonetheless, consuming epigallocatechin gallate (EGCG) and ketone bodies (especially β-hydroxybutyrate (βHB)) produced after metabolising coconut oil, have exhibited anti-inflammatory effects and a decrease in body fat. In addition, butyrylcholinesterase (BuChE), seems to be related to the pathogenesis of the disease associated with inflammation, and serum concentrations have been related to lipid metabolism. Objective. The aim of the study was to determine the role of BuChE in the changes caused after treatment with EGCG and ketone bodies on the levels of body fat and inflammation state in MS patients. (2) Methods. A pilot study was conducted for 4 months with 51 MS patients who were randomly divided into an intervention group and a control group. The intervention group received 800 mg of EGCG and 60 mL of coconut oil, and the control group was prescribed a placebo. Fat percentage and concentrations of the butyrylcholinesterase enzyme (BuChE), paraoxonase 1 (PON1) activity, triglycerides, interleukin 6 (IL-6), albumin and βHB in serum were measured. (3) Results. The intervention group exhibited significant decreases in IL-6 and fat percentage and significant increases in BuChE, βHB, PON1, albumin and functional capacity (determined by the Expanded Disability Status Scale (EDSS)). On the other hand, the control group only exhibited a decrease in IL-6. After the intervention, BuChE was positively correlated with the activity of PON1, fat percentage and triglycerides in the intervention group, whereas these correlations were not observed in the control group (4). Conclusions. BuChE seems to have an important role in lipolytic activity and the inflammation state in MS patients, evidenced after administering EGCG and coconut oil as a βHB source.

show abstract

“…Contrarily, Pilutti et al (10) found no significant difference in various mobility outcomes, such as walking speed and endurance, based on the BMI status. Sebastião et al (12) showed that patients with MS and obesity have lower cardiorespiratory fitness than overweight and non-obese groups. Studies that investigate the relationship between the lower limb functions and obesity in people with MS have presented mixed results.…”

Section: Introductionmentioning

confidence: 99%

The Association of Obesity with Walking and Balance Control in Fully Ambulatory People with Multiple Sclerosis According to Two Different Classifications

Özdoğar¹,

Kahraman²,

Ertekin³

et al. 2021

jmrs

View full text Add to dashboard Cite

Objective: Previous studies have reported that people with obesity have slower walking speed, poor balance control, and more energy expenditure during gait than patients without obesity. However, little is known about the effect of obesity on walking and balance control in people with multiple sclerosis (MS). This study aimed to investigate the associations of obesity with walking and balance control in fully ambulatory people with MS using two different obesity classifications. Materials and Methods: This study included 210 fully ambulatory people with MS. Obesity classification recommended for MS and obesity classification by the World Health Organization (WHO) were used. Outcome measures included walking speed [timed 25-foot walk (T25FW)], walking endurance [six-minute walk test (6MWT)], perceived walking impairment [12-item ms walking scale (MSWS-12)], and balance control [timed up and go (TUG) test].Results: According to recommendations for MS and WHO classification, 105 (50%) and 28 (13.3%) participants were classified as obese, respectively. Both groups revealed that patients who are overweight and obese have lower scores in T25FW, 6MWT, and TUG tests, whereas higher scores on the MSWS-12 than patients without obesity, with a significant difference (p<0.05). Conclusion:People who are overweight and obese with MS have poorer performance on walking speed, walking endurance, perceived walking impairment, and balance control than non-obese counterparts. Future longitudinal studies should investigate the effects of losing weight on walking and balance in people with MS.

show abstract

Body mass index and cardiorespiratory fitness in persons with multiple sclerosis

Abstract: The findings suggest that BMI has a negative impact on CRF in pwMS, with a marked reduction in CRF for those classified as obese compared to those in the normal and overweight category.

Cited by 6 publications

References 26 publications

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

Possible Role of Butyrylcholinesterase in Fat Loss and Decreases in Inflammatory Levels in Patients with Multiple Sclerosis after Treatment with Epigallocatechin Gallate and Coconut Oil: A Pilot Study

The Association of Obesity with Walking and Balance Control in Fully Ambulatory People with Multiple Sclerosis According to Two Different Classifications

Contact Info

Product

Resources

About